CN110810852A - 一种调节心血管功能的蚯蚓冻干粉的制备方法 - Google Patents
一种调节心血管功能的蚯蚓冻干粉的制备方法 Download PDFInfo
- Publication number
- CN110810852A CN110810852A CN201911064135.3A CN201911064135A CN110810852A CN 110810852 A CN110810852 A CN 110810852A CN 201911064135 A CN201911064135 A CN 201911064135A CN 110810852 A CN110810852 A CN 110810852A
- Authority
- CN
- China
- Prior art keywords
- dried powder
- regulating
- freeze
- cardiovascular function
- earthworm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000361919 Metaphire sieboldi Species 0.000 title claims abstract description 26
- 239000000843 powder Substances 0.000 title claims abstract description 23
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 19
- 230000009084 cardiovascular function Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000002244 precipitate Substances 0.000 claims abstract description 31
- 239000006228 supernatant Substances 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 241001233061 earthworms Species 0.000 claims abstract description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 239000008367 deionised water Substances 0.000 claims description 14
- 229910021641 deionized water Inorganic materials 0.000 claims description 14
- 102000012479 Serine Proteases Human genes 0.000 claims description 13
- 108010022999 Serine Proteases Proteins 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000012610 weak anion exchange resin Substances 0.000 claims description 7
- 241000243684 Lumbricus Species 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 16
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 238000000605 extraction Methods 0.000 abstract description 12
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 abstract description 2
- 230000002358 autolytic effect Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000004576 sand Substances 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000007696 Kjeldahl method Methods 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010056697 Tissue anoxia Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000030451 Vascular dementia disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开了一种调节心血管功能的蚯蚓冻干粉的制备方法,属于保健品领域。先将蚯蚓自溶酶提取,沉淀物进行酶解,再水醇提取。本发明现将蚯蚓粉碎后在清水中自溶解,将能够溶解在水中的蛋白质提取至上清液中。再将沉淀物再次进行酶解和醇提,能够提高蚯蚓中蛋白质的提取含量,提取工艺简单,提取效率高。
Description
技术领域
本发明涉及保健品领域,具体涉及一种调节心血管功能的蚯蚓冻干粉的制备方法。
背景技术
血管性痴呆是指大脑功能衰退,特别是与智能有关的功能全面衰退的综合征,通常包括记忆力、认知力、情绪与行为异常等一系列的症状与体征,其中脑血管病变所致的脑组织供血不足是本病发生的根本原因;北京统计的患病率为1.37%,并有增长趋势。目前血管性痴呆疾病发病形势十分严峻,随着社会老龄化的到来,血管性痴呆患者日益增多,晚期往往导致生活完全不能自理,不仅给患者的正常生活造成了严重的影响,给家庭及社会带来沉重的负担;目前中西医缺少特效型的治疗药物,多限于使用脑神经营养药物或临床对症处理,疗程长,费用昂贵,达不到理想的治疗效果,同时尚未有单味中药治疗本疾病的药物。
蚯蚓又称地龙,体内营养十分丰富,蛋白质含量平均为50%,最高可达70%,且富含多种氨基酸、维生素、矿物质元素及微量元素,并含有对人体有益的酶类、糖类、肽类等多种活性成分如:溶栓酶、抗氧化酶、抗菌肽、溶血素等。具有抗血栓,抗肿瘤,调节免疫力,降压,镇痛消炎的作用。而当前血栓性疾病的发病率较高,而地龙中的蛋白能够抑制血管紧张素转化酶的活性,降低血压。而其中地龙蛋白中的氨基酸能够促进神经细胞更新,调节神经递质代谢,维护神经功能及抗脑组织缺氧的作用。苯丙氨酸能够降低心血管疾病的发病率,抵抗自由基。赖氨酸又可有效预防血栓,与蛋氨酸相互配合能够抑制高血压。精氨酸能够抑制血小板聚集,减少氧自由基损伤。饱和与不饱和脂肪酸能够调节血脂,降低胆固醇,预防动脉硬化、心血管疾病和大脑的机制。
蚯蚓提取物中大部分为大分子蛋白质和小分子氨基酸,其中小分子氨基酸主要亮氨酸、谷氨酸、天冬氨酸、缬氨酸、赖氨酸、精氨酸、丙氨酸、甘氨酸、丝氨酸、苏氨酸、蛋氨酸、苯丙氨酸、脯氨酸、组氨酸和酪氨酸等。而多肽更容易被人体吸收,对疾病的防御更好。现有大部分的蚯蚓蛋白提取物主要分为水提或纯提,提取含量不高,且纯度低,程序复杂。
发明内容
为了解决上述问题,本发明提出了一种提取效果好,多肽含量高、纯度高的调节心血管功能的蚯蚓冻干粉的制备方法。
为了实现上述目的,本发明是通过以下技术方案来实现的:
一种调节心血管功能的蚯蚓冻干粉的制备方法,包括以下步骤:
(1)将蚯蚓洗净置于清水中,放置浸泡12-24h吐沙;
(2)将蚯蚓粉碎制浆,加入去离子水后,高速匀浆,离心,取上清液A和沉淀物;
(3)在步骤(2)中的沉淀物再次加入去离子水后,再加入蛋白酶酶解反应,离心取上清液B;
(4)将上清液A和上清液B合并,再加入溶解剂后,再次离心取沉淀物,上弱阴离子交换树脂柱,用NaCl溶液洗脱,收集洗脱液,透析除盐,溶液冷冻干燥,即得。
进一步的,步骤(3)中所述蛋白酶为丝氨酸蛋白酶。
进一步的,步骤(3)中所述酶解反应的温度为35-40℃,酶解时间为1-2.5h。
进一步的,步骤(3)中蛋白酶的加入量为步骤(2)中沉淀物质量的5-10%。
进一步的,步骤(4)中所述的溶解剂为65-90%的乙醇。
进一步的,步骤(4)中所述的溶解剂为75%的乙醇。
本发明调节心血管功能的蚯蚓冻干粉的制备方法,其有益效果在于:
(1)本发明现将蚯蚓粉碎后在清水中自溶解,将能够溶解在水中的蛋白质提取至上清液中。再将沉淀物再次进行酶解和醇提,能够提高蚯蚓中蛋白质的提取含量。
(2)在酶解的过程中,加入丝氨酸蛋白酶,能够将大分子的蛋白质分解成小分子,提高蛋白粉中小分子氨基酸的含量,尤其是提高了苯丙氨酸、赖氨酸和丝氨酸的含量。能够使蛋白粉提高在心血管疾病方面的应用,降低心血管疾病的发病率,抵抗自由基、有效预防血栓,调节血脂,降低胆固醇,预防动脉硬化、心血管疾病和大脑的机制。
(3)在提取过程中采用65-90%的乙醇,尤其是75%的乙醇,能够促进氨基酸的溶出,提高蛋白质提取效果;防止蛋白质变质,提高蛋白质的利用率。
(4)本发明提取工艺简单,提取效率高。
具体实施方式
下面结合具体实施例来进一步详细说明本发明。
实施例1
一种调节心血管功能的蚯蚓冻干粉的制备方法,包括以下步骤:
(1)将蚯蚓洗净置于清水中,放置浸泡12h吐沙;
(2)将蚯蚓粉碎制浆,加入去离子水后,高速匀浆30Min,离心,取上清液A和沉淀物;
(3)在步骤(2)中的沉淀物再次加入去离子水后,再加入丝氨酸蛋白酶酶解反应,丝氨酸蛋白酶的加入量为沉淀物质量的5%;酶解反应的温度为40℃,酶解时间为1h离心取上清液B;
(4)将上清液A和上清液B合并,再加入75%的乙醇后,再次离心取沉淀物,上弱阴离子交换树脂柱,用NaCl溶液洗脱,收集洗脱液,透析除盐,溶液冷冻干燥,即得。
实施例2
一种调节心血管功能的蚯蚓冻干粉的制备方法,包括以下步骤:
(1)将蚯蚓洗净置于清水中,放置浸泡24h吐沙;
(2)将蚯蚓粉碎制浆,加入去离子水后,高速匀浆60Min,离心,取上清液A和沉淀物;
(3)在步骤(2)中的沉淀物再次加入去离子水后,再加入丝氨酸蛋白酶酶解反应,丝氨酸蛋白酶的加入量为沉淀物质量的10%;酶解反应的温度为35℃,酶解时间为1.5h离心取上清液B;
(4)将上清液A和上清液B合并,再加入65%的乙醇后,再次离心取沉淀物,上弱阴离子交换树脂柱,用NaCl溶液洗脱,收集洗脱液,透析除盐,溶液冷冻干燥,即得。
实施例3
一种调节心血管功能的蚯蚓冻干粉的制备方法,包括以下步骤:
(1)将蚯蚓洗净置于清水中,放置浸泡16h吐沙;
(2)将蚯蚓粉碎制浆,加入去离子水后,高速匀浆40Min,离心,取上清液A和沉淀物;
(3)在步骤(2)中的沉淀物再次加入去离子水后,再加入丝氨酸蛋白酶酶解反应,丝氨酸蛋白酶的加入量为沉淀物质量的8%;酶解反应的温度为37℃,酶解时间为2h离心取上清液B;
(4)将上清液A和上清液B合并,再加入90%的乙醇后,再次离心取沉淀物,上弱阴离子交换树脂柱,用NaCl溶液洗脱,收集洗脱液,透析除盐,溶液冷冻干燥,即得。
实施例4
一种调节心血管功能的蚯蚓冻干粉的制备方法,包括以下步骤:
(1)将蚯蚓洗净置于清水中,放置浸泡20h吐沙;
(2)将蚯蚓粉碎制浆,加入去离子水后,高速匀浆50Min,离心,取上清液A和沉淀物;
(3)在步骤(2)中的沉淀物再次加入去离子水后,再加入丝氨酸蛋白酶酶解反应,丝氨酸蛋白酶的加入量为沉淀物质量的6%;酶解反应的温度为38℃,酶解时间为2.5h离心取上清液B;
(4)将上清液A和上清液B合并,再加入80%的乙醇后,再次离心取沉淀物,上弱阴离子交换树脂柱,用NaCl溶液洗脱,收集洗脱液,透析除盐,溶液冷冻干燥,即得。
实施例5
一种调节心血管功能的蚯蚓冻干粉的制备方法,包括以下步骤:
(1)将蚯蚓洗净置于清水中,放置浸泡24h吐沙;
(2)将蚯蚓粉碎制浆,加入去离子水后,高速匀浆50Min,离心,取上清液A和沉淀物;
(3)在步骤(2)中的沉淀物再次加入去离子水后,再加入丝氨酸蛋白酶酶解反应,丝氨酸蛋白酶的加入量为沉淀物质量的8%;酶解反应的温度为37℃,酶解时间为2h离心取上清液B;
(4)将上清液A和上清液B合并,再加入85%的乙醇后,再次离心取沉淀物,上弱阴离子交换树脂柱,用NaCl溶液洗脱,收集洗脱液,透析除盐,溶液冷冻干燥,即得。
物质检测:
对蛋白冻干粉总氮含量及游离氨基酸含量的检测
参照GB5009-2010《食品中蛋白质的测定》规定的方法,采用凯氏定氮法,对蚯蚓小分子多肽提取物总氮含量进行分析。参照GB/T5009.124-2003《食品中氨基酸的测定》规定的方法,用磺基水酸溶液溶解样品并定容,样品溶液摇匀后过滤、离心,采用日立L-8900氨基酸分析仪测定上清液对蚯蚓小分子多肽提取物中种游离氨基酸进行分析。
经过凯氏定氮法测定,每100g冻干粉中,总氮的含量为14.8g,按照6.25的换算系数蛋白质的含量在92.5%。由此可见提取出的蛋白质冻干粉含量高,灰分含量少,纯度高。且游离态氨基酸的总含量为67.2%。每100g样品中含有丝氨酸1.79g、精氨酸2.41g、赖氨酸1.84g、苯丙氨酸3.29g。由此可以看出,本发明的提取方法中苯丙氨酸、赖氨酸、精氨酸和丝氨酸含量高,能够有效降低心血管疾病的发病率,抵抗自由基,预防血栓、动脉硬化、心血管疾病。
以上对本发明实施例所提供的技术方案进行了详细介绍,本文中应用了具体个例对本发明实施例的原理以及实施方式进行了阐述,以上实施例的说明只适用于帮助理解本发明实施例的原理;同时,对于本领域的一般技术人员,依据本发明实施例,在具体实施方式以及应用范围上均会有改变之处,综上所述,本说明书内容不应理解为对本发明的限制。
Claims (6)
1.一种调节心血管功能的蚯蚓冻干粉的制备方法,其特征在于:包括以下步骤:
(1)将蚯蚓洗净置于清水中,放置浸泡12-24h吐沙;
(2)将蚯蚓粉碎制浆,加入去离子水后,高速匀浆,离心,取上清液A和沉淀物;
(3)在步骤(2)中的沉淀物再次加入去离子水后,再加入蛋白酶酶解反应,离心取上清液B;
(4)将上清液A和上清液B合并,再加入溶解剂后,再次离心取沉淀物,上弱阴离子交换树脂柱,用NaCl溶液洗脱,收集洗脱液,透析除盐,溶液冷冻干燥,即得。
2.根据权利要求1所述调节心血管功能的蚯蚓冻干粉的制备方法,其特征在于:步骤(3)中所述蛋白酶为丝氨酸蛋白酶。
3.根据权利要求1所述调节心血管功能的蚯蚓冻干粉的制备方法,其特征在于:步骤(3)中所述酶解反应的温度为35-40℃,酶解时间为1-2.5h。
4.根据权利要求1所述调节心血管功能的蚯蚓冻干粉的制备方法,其特征在于:步骤(3)中蛋白酶的加入量为步骤(2)中沉淀物质量的5-10%。
5.根据权利要求1所述调节心血管功能的蚯蚓冻干粉的制备方法,其特征在于:步骤(4)中所述的溶解剂为65-90%的乙醇。
6.根据权利要求1所述调节心血管功能的蚯蚓冻干粉的制备方法,其特征在于:步骤(4)中所述的溶解剂为75%的乙醇。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911064135.3A CN110810852A (zh) | 2019-11-04 | 2019-11-04 | 一种调节心血管功能的蚯蚓冻干粉的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911064135.3A CN110810852A (zh) | 2019-11-04 | 2019-11-04 | 一种调节心血管功能的蚯蚓冻干粉的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110810852A true CN110810852A (zh) | 2020-02-21 |
Family
ID=69552238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911064135.3A Pending CN110810852A (zh) | 2019-11-04 | 2019-11-04 | 一种调节心血管功能的蚯蚓冻干粉的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110810852A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111450120A (zh) * | 2020-04-26 | 2020-07-28 | 安溪县桃源有机茶场有限公司 | 一种蚯蚓全粉及其制备方法和应用 |
CN115736251A (zh) * | 2022-11-30 | 2023-03-07 | 山东神乐生物科技有限公司 | 一种蚯蚓冻干粉的制备方法及应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003259837A (ja) * | 2002-03-11 | 2003-09-16 | Gold Life:Kk | ミミズを原料とする健康補助食品の製造方法 |
JP2006096673A (ja) * | 2004-09-28 | 2006-04-13 | Mihara Lr Kenkyusho:Kk | ミミズ製品の製造方法 |
CN1966517A (zh) * | 2006-03-03 | 2007-05-23 | 上海中医药大学 | 蚯蚓蛋白ep-2及其分离方法和应用 |
CN102578362A (zh) * | 2012-03-28 | 2012-07-18 | 常熟市汇康食品厂 | 一种蚯蚓复合蛋白粉 |
CN103146788A (zh) * | 2013-02-28 | 2013-06-12 | 珠海博康药业有限公司 | 一种大豆肽的酶法制备方法 |
CN103146789A (zh) * | 2013-02-28 | 2013-06-12 | 珠海博康药业有限公司 | 一种胶原蛋白的制备方法 |
CN105177096A (zh) * | 2015-10-21 | 2015-12-23 | 哈尔滨工业大学 | 一种抗凝血肽的酶解制备方法 |
CN106074612A (zh) * | 2016-07-22 | 2016-11-09 | 杨凌三度蚯蚓科技有限公司 | 一种调节心血管功能的蚯蚓冻干粉及其制备方法和用途 |
-
2019
- 2019-11-04 CN CN201911064135.3A patent/CN110810852A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003259837A (ja) * | 2002-03-11 | 2003-09-16 | Gold Life:Kk | ミミズを原料とする健康補助食品の製造方法 |
JP2006096673A (ja) * | 2004-09-28 | 2006-04-13 | Mihara Lr Kenkyusho:Kk | ミミズ製品の製造方法 |
CN1966517A (zh) * | 2006-03-03 | 2007-05-23 | 上海中医药大学 | 蚯蚓蛋白ep-2及其分离方法和应用 |
CN102578362A (zh) * | 2012-03-28 | 2012-07-18 | 常熟市汇康食品厂 | 一种蚯蚓复合蛋白粉 |
CN103146788A (zh) * | 2013-02-28 | 2013-06-12 | 珠海博康药业有限公司 | 一种大豆肽的酶法制备方法 |
CN103146789A (zh) * | 2013-02-28 | 2013-06-12 | 珠海博康药业有限公司 | 一种胶原蛋白的制备方法 |
CN105177096A (zh) * | 2015-10-21 | 2015-12-23 | 哈尔滨工业大学 | 一种抗凝血肽的酶解制备方法 |
CN106074612A (zh) * | 2016-07-22 | 2016-11-09 | 杨凌三度蚯蚓科技有限公司 | 一种调节心血管功能的蚯蚓冻干粉及其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
余元勋: "《中国分子中药学》", 31 August 2017, 安徽科学技术出版社 * |
刘波等: "蚯蚓外源酶与内源酶酶解产物分析", 《天然产物研究与开发》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111450120A (zh) * | 2020-04-26 | 2020-07-28 | 安溪县桃源有机茶场有限公司 | 一种蚯蚓全粉及其制备方法和应用 |
CN115736251A (zh) * | 2022-11-30 | 2023-03-07 | 山东神乐生物科技有限公司 | 一种蚯蚓冻干粉的制备方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10455849B2 (en) | Method for the preparation of a protein peptide, a protein peptide and use thereof | |
JP5763203B2 (ja) | トウモロコシ降圧活性ペプチドを調製するための工業的方法 | |
CN104774896A (zh) | 带鱼鱼骨铁螯合胶原肽制备方法 | |
CN110810852A (zh) | 一种调节心血管功能的蚯蚓冻干粉的制备方法 | |
CN108893515B (zh) | 高f值寡肽及其制备方法 | |
CN109468357A (zh) | 一种脾氨肽的制备方法 | |
KR101449804B1 (ko) | 홍어 껍질 유래 젤라틴 추출물 및 상기 추출물로부터 분리한 펩타이드를 유효성분으로 포함하는 항고혈압 조성물 | |
CN108546281A (zh) | 一种人参低聚肽及其制备方法和应用 | |
CN107475342A (zh) | 一种蜗牛活性肽的提取方法 | |
CN102286591A (zh) | 一种酵母来源活性多肽的制备方法 | |
CN114214366A (zh) | 一种预防和治疗贫血的小肽粉和血红素之肽红复方药物及其制备方法和应用 | |
CN112501229B (zh) | 一种牛骨胶原肽的生产工艺 | |
CN111329988A (zh) | 一种富含游离精氨酸的阿胶肽含片及其制备方法 | |
CN111690704A (zh) | 一种鹿茸多肽的制备方法及其应用 | |
CN104945501A (zh) | 一种带鱼鱼骨铁螯合胶原肽 | |
KR101780643B1 (ko) | 효소분해를 이용한 헤파린의 정제 방법 | |
CN113087773B (zh) | 一种具有降血糖和抗氧化功能的牦牛骨肽及其制备方法 | |
CN102787154B (zh) | 一种乌鸡低聚肽的制备及其活性肽段分离、鉴定方法 | |
CN114287638A (zh) | 一种小分子复合寡肽及其制备方法和应用 | |
CN106831938A (zh) | 一种制备阿胶小分子低肽的方法 | |
CN108676834A (zh) | 一种大蒜抗肿瘤活性多肽 | |
CN109402206B (zh) | 一种疣荔枝螺降压肽的制备方法 | |
CN117327142A (zh) | 一种规模化生产地龙蛋白的方法 | |
CN114634960B (zh) | 一种食用型胸腺肽的制备方法 | |
CN102697810B (zh) | 一种肌氨肽苷提取物及其组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200221 |